TLR4 and ductal breast carcinoma in situ: We have previously demonstrated that tumor antigen-bearing dendritic cells generated using IFN-γ and the TLR-4 agonist LPS (referred to here as DC1 dendritic cells) promote a targeted immune response in patients with ductal carcinoma in situ [13].